<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
PREMIER RESEARCH WORLDWIDE, LTD
(Name of Issuer)
Common Stock
(Title of Class of Securities)
740568 10 0
(CUSIP Number)
The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and a subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(Continued on the following pages)
Page 1 of 5 Pages
<PAGE>
CUSIP NO. 740568 10 0
-----------
- --------------------------------------------------------------------------------
1) Name of Reporting Person
S.S. or I.R.S. Identification Nos. of Above Person
Joel Morganroth, M.D. ###-##-####
- --------------------------------------------------------------------------------
2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3) SEC Use Only
- --------------------------------------------------------------------------------
4) Citizenship or Place of Organization
United States
- --------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power 145,075
Beneficially -----------------------------------------------------
Owned By Each (6) Shared Voting Power 9,600
Reporting -----------------------------------------------------
Person (7) Sole Dispositive Power 145,075
With -----------------------------------------------------
(8) Shared Dispositive Power 9,600
- --------------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned by Each Reporting Person
900,000 (disclaims beneficial ownership of 525,225 shares)
- --------------------------------------------------------------------------------
10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) [ ]
- --------------------------------------------------------------------------------
11) Percent of Class Represented by Amount in Row (9)
12.6%
- --------------------------------------------------------------------------------
12) Type of Reporting Person (See Instructions)
IN
- --------------------------------------------------------------------------------
-2-
<PAGE>
Schedule 13G
Item l(a) Name of Issuer:
Premier Research Worldwide, Ltd.
Item l(b) Address of Issuer's Principal Executive Offices:
Premier Research Worldwide, Ltd.
124 S. 15th Street
Philadelphia, Pennsylvania 19102-3010
Item 2(a) Name of Person Filing:
Joel Morganroth, M.D.
Item 2(b) Address of Principal Business Office:
124 S. 15th Street
Philadelphia, Pennsylvania 19102-3010
Item 2(c) Citizenship:
United States
Item 2(d) Title of Class of Securities:
Common Stock, $.01 Par Value
Item 2(e) CUSIP Number:
740568 10 0
Item 3: Not Applicable
Item 4: Ownership:
Dr. Morganroth, as described more fully below, may be deemed
to own beneficially (as that term is defined in Rule 13d-3 of the
Securities Exchange Act of 1934, as amended) 900,000 shares of the
common stock of Premier Research Worldwide, Ltd., representing 12.6% of
the outstanding shares of common stock. Dr. Morganroth's beneficial
ownership is as follows:
-3-
<PAGE>
1. 145,075 shares directly owned by Dr.
Morganroth, as to which he has sole voting
and dispositive power.
2. 9,600 shares owned by a pension plan, as
to which Dr. Morganroth has shared voting
and dispositive power.
3. 220,100 shares underlying currently
exercisable options granted under a
Corporation stock option plan.
4. 495,225 shares held in a trust, the trustee
of which is Dr. Morganroth's wife and the
beneficiaries of which are Dr. Morganroth's
children. Dr. Morganroth disclaims
beneficial ownership of these shares.
5. 30,000 shares of which Dr. Morganroth may
be deemed to be the beneficial owner due
to the fact that Dr. Morganroth is
entitled to a credit against the principal
and interest owing on a promissory note
payable to a third party, equal to the
market value of 30,000 shares of common
stock on or in certain cases before the
note's maturity date. Dr. Morganroth
disclaims beneficial ownership of these
shares.
Item 5: Not Applicable
Item 6: Not Applicable
Item 7: Not Applicable
Item 8: Not Applicable
Item 9: Not Applicable
Item 10: Not Applicable
-4-
<PAGE>
Signature
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in my statement is true, complete and
correct.
Dated: February 2, 1998
/s/Joel Morganroth, M.D.
----------------------------
[Signature]
Joel Morganroth, M.D.
----------------------------
Name/Title
-5-
